Dong-A ST to acquire AbTis
Not yet reviewed: summarised from filings and press reports; figures may differ between reports. Please check the original sources.
- Deal value
- —
- Stake
- —
- Implied 100%
- —
- Revenue
- —
- Op. income
- —
- Multiples
- —
- Target
- AbTis · ADC drug development
- Buyer
- Dong-A ST · SI
- Seller
- Existing shareholders
- Structure
- —
- Announced
- Dec 20, 2023
- Closed
- —
- Stage
- Announced
Target
AbTis is an antibody-drug conjugate (ADC) company that owns 'AbClick', a third-generation ADC linker technology enabling site-selective drug conjugation without antibody modification. Its lead pipeline asset is AT-211, a Claudin18.2-targeting ADC candidate.
Deal rationale
Dong-A ST said it acquired control of AbTis together with its third-generation ADC linker platform and pipeline to secure a new growth engine in R&D. The company said it plans to build a proprietary ADC platform over the medium to long term and expand into ADC CDMO services, and to pursue synergies among Dong-A ST, ST Pharm and STgenBio. AbTis was reported to become a subsidiary within 2023.
Press coverage
- 데일리팜 (2023-12-20): “동아ST, 앱티스 인수…ADC 신약 개발 본격화”
- 바이오스펙테이터 (2023-12-20): “구체적인 계약 규모를 밝히지 않았다”
- 데일리팜 (): “동아에스티가 2023년 말부터 1년 동안 앱티스에 투자한 자금은 총 556억원에 달했다.”
This is a data entry summarising filings and press reports. Please check the original sources for the figures.